What happenedForesite Capital Management IV, LLC disclosed a new stake in Cytokinetics (CYTK 2.28%), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly report filed with the U.S. Securities and Exchange Commission on Nov. 14, 2025 (SEC filing). The fund’s total reportable U.S. equity assets stood at $182.61 million across six holdings after the filing.What else to knowThis is a new position for Foresite Capital Management IV, LLC, representing 13.8% of ...